Study drug for advanced solid tumors that stopped responding
Part of Cancer, Lungs & breathing, Skin clinical trials.
This early study tests a new medicine (JAB-2485) in adults with advanced solid tumors (cancers that have spread or grown locally). You may join to see if it can shrink tumors or control the disease when other treatments haven’t worked or weren’t tolerated.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can do daily activities fairly well (ECOG 0–1).
- Your cancer must be confirmed as metastatic or locally advanced solid tumor on biopsy or cells.
- You need a stored tumor sample from the past that can be provided.
- Your cancer should have been treated before but is no longer responding or you couldn’t tolerate it.
- You must have at least one measurable tumor spot on scans (per RECIST).
- You must be able to take the study medicine by mouth (swallow and keep it down).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new experimental drug for people with advanced solid tumors that have not responded to standard treatments. It aims to find a safe dose and see if the drug can shrink tumors.
This trial tests a new investigational drug (JNJ-87890387) for people with certain advanced solid tumors that have spread or cannot be removed by surgery. It aims to see if the drug is safe and effective.
This early study (Phase 1/2) tests a new medicine (JAB-8263) in adults with advanced solid tumors or recurrent/refractory AML. It aims to find a safe dose and see whether it can shrink tumors or control the cancer.
This trial tests a new drug called JSKN027 for people with advanced solid tumors (cancers that have spread) that have not responded to standard treatments. The goal is to see if the drug is safe and can help shrink tumors.
This trial tests a combination of two new treatments (QLP2117 and QL2107) for people with advanced solid tumors that have not responded to standard therapy. The goal is to see if the combination can shrink tumors or slow cancer growth.
This trial tests two new drugs, JS212 and JS213, alone or together, for people with certain advanced cancers that have stopped responding to standard treatments. The goal is to see if these drugs can shrink tumors or slow cancer growth.
Hear when a new ER+ Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.